December 5, 2019 -FDA Approval Extends Label to Include MolecuLight i:X Wound Care Device Features
TORONTO, Canada – (December 5, 2019) MolecuLight Inc., the world’s leader in handheld fluorescence imaging for real-time visualization of fluorescence in wounds, has received FDA 510(k) clearance for its i:X® handheld fluorescence imaging device for use in
… Read MoreNovember 4, 2019 -Category lll CPT Code Reflects Clinical Evidence and Value of Fluorescence Imaging
TORONTO, Canada – (November 4, 2019) MolecuLight Inc., the world’s leader in handheld fluorescence imaging for real-time visualization of bacteria for chronic wounds, has been informed by the American Medical Association (AMA) that in its summary of panel
… Read MoreOctober 11, 2019 -
Multiple Trials Illustrate the Significant Clinical Benefit of MolecuLight’s Point-of-Care Fluorescence Imaging Device for Chronic Wound Management
LAS VEGAS, USA and TORONTO, Canada – (October 11, 2019) MolecuLight Inc., the world’s leader in handheld fluorescence imaging for real-time visualization of bacteria for chronic wounds and its i:X point-of-care fluorescence imaging
… Read MoreOctober 4, 2019 -
Point-of-Care Fluorescence Imaging for Chronic Wounds and its Significant Clinical Benefits are Featured at the Largest Canadian Wound Care Conference in 5 Clinical Talks and Posters
NIAGARA FALLS, Canada and TORONTO, Canada – (October 4, 2019) MolecuLight Inc., the world’s leader in handheld fluorescence imaging for real-time visualization
… Read MoreAugust 19, 2019 -
TORONTO, Canada – (August 19, 2019) MolecuLight Inc., the world’s leader in handheld fluorescence imaging for real-time visualization of bacteria for chronic wounds, announced it has secured a $7.5 million USD term loan from Oxford Finance LLC, a specialty finance firm providing senior debt to life sciences and healthcare services
… Read MoreAugust 14, 2019 -
photonamic GmbH & Co. KG (Head office: Pinneberg, Germany; CEO: Ulrich Kosciessa, Ph.D.) (“photonamic”), a subsidiary of SBI Holdings, Inc. (Head office: Minato-ku,Tokyo; Representative Director, President and CEO: Yoshitaka Kitao) is engaged in the business of pharmaceutical development of 5-aminolevulinic acid (“5-ALA”) (*) hereby announces the acquisition of the
… Read MoreJanuary 15, 2018 -
Read the abstract for the latest publication from Lt Col. Steven Jeffery published this month in the Journal of Wound Care.
ABSTRACT Objective:Current standard diagnostic practice of bacterial infections by visual inspection under white light is subjective, and microbiological sampling is suboptimal due to high false negative rates and
… Read MoreDecember 7, 2017 -Are standard debridement practices maximizing removal of bioburden?
The current gold standard for tissue management in diabetic foot ulcers is regular sharp debridement to reduce bioburden. However, a recent study by Rose Raizman, RN-EC MSc, a wound care clinician, which used bacterial fluorescence imaging with the MolecuLight i:X after initial, aggressive debridement
… Read MoreOctober 17, 2017 -
TORONTO, CANADA. MolecuLight, a global leader in fluorescence image-guidance solutions, is pleased to announce the appointment of industry veteran Anil Amlani as Chief Executive Officer effective September 29, 2017.
William Wignall, Chairman of the Board at MolecuLight, commented, “The Board is delighted to welcome Anil as MolecuLight’s new CEO. Anil
… Read More
MolecuLight is SOC ll®
Type l Accredited:
MolecuLight awarded
Premier’s Technology
Breakthrough Designation
MolecuLight i:X
is designated as a:
MolecuLight included
in ISWCAP Consensus
Guidelines:
MolecuLight is a proud
corporate member of:
©2025
The MolecuLight® i:X and MolecuLightDX™ Imaging Devices are approved by Health Canada for sale in Canada and has CE marking for sale in the European Union.
The MolecuLight™ i:X and DX Imaging Devices have received FDA clearance.